health π¬ Finerenone linked to higher kidney stone risk
A comparative real-world evidence study found that finerenone significantly increased the risk of incident nephrolithiasis compared to other drugs. This study utilized data from the TriNetX US Collaborative Network covering June 2021 to June 2024. Finerenone showed higher hazard ratios against spironolactone, SGLT2i, and ACEi/ARB across multiple subgroups. The findings suggest that nephrolithiasis risk must be considered when treating CKD patients with finerenone. Clinicians should review this evidence to manage stone risk when prescribing these medications. π§